EU Greenlights Merck’s KEYTRUDA® Combo for High-Risk NSCLC Treatment
Merck, also known as MSD outside of the United States and Canada, has announced today that the European Commission (EC) has granted approval for KEYTRUDA, Merck’s anti-PD-1 therapy. This approval…
Breakthrough FDA Approval: Merck’s WINREVAIR™ Revolutionizes PAH Treatment for Adults
Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has given approval for sotatercept-csrk, branded as WINREVAIR™ in…
AbbVie’s Acquisition of Landos Biopharma Bolsters its Reach in Inflammatory and Autoimmune Conditions
AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) have announced a definitive agreement today, wherein AbbVie will acquire Landos, a clinical stage biopharmaceutical company primarily focused…
Novo Nordisk’s Acquisition of Cardior Pharmaceuticals: Enhancing Cardiovascular Disease Pipeline
Novo Nordisk and Cardior Pharmaceuticals have announced a significant acquisition deal, with Novo Nordisk set to acquire Cardior for up to 1.025 billion Euros. This includes an upfront payment along…
Awiqli®: European Authorities Recommend Approval for Weekly Basal Insulin Icodec in Diabetes Treatment
Novo Nordisk has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion, recommending the marketing authorization for Awiqli® (the branded…
Comprehensive Research on the Global Covid-19 Diagnostic Market for 2024: Executive and Consultant Guides Available – ResearchAndMarkets.com
The “Global Covid-19 Diagnostic Market Forecast by Technology, Product, Channel and Country with Executive and Consultant Guides” report has been added to ResearchAndMarkets.com’s offering. Amidst signs of the pandemic easing, Covid-19 continues to reshape…
Gilead Sciences Announces Completion of Acquisition of CymaBay
Gilead Sciences, Inc. (Nasdaq: GILD) has finalized its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for an estimated total equity value of about $4.3 billion. This strategic move enhances Gilead’s…
GenSight Biologics Releases Comprehensive Financial Summary for Fiscal Year 2023
GenSight Biologics, a biopharmaceutical company listed on Euronext under the ticker symbol SIGHT and ISIN FR0013183985, eligible for PEA-PME, has disclosed its consolidated financial performance for the full year 2023.…
2024 Biopharma-Site Network Pulse Report: Insights from IQVIA, ICON, Parexel, Fortrea, PPD/Thermo Fisher, and Syneos Health – Research And Markets.com
The “2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report” has been added to ResearchAndMarkets.com’s offering. The landscape of biopharmaceutical clinical development is in a constant state of flux and progression. While major…
Otsuka Pharma’s Indonesian Subsidiaries Earn Exemplar Award from EWTB for Tuberculosis Eradication Efforts
Otsuka Pharmaceutical proudly announces that its subsidiaries in Indonesia, PT Otsuka Indonesia (PTOI) and PT Amerta Indah Otsuka (PTAIO), have been honored with the prestigious 2024 Ending Workplace Tuberculosis (EWTB)…
CHMP Recommends Novartis Fabhalta® for Adult Paroxysmal Nocturnal Hemoglobinuria (PNH)
Novartis Unveils Positive CHMP Endorsement for Fabhalta® in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH) Novartis has disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
FDA Fully Approves ELAHERE® for Specific Ovarian Cancer Patients
AbbVie (NYSE: ABBV) has announced today that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for treating folate receptor alpha (FRα)-positive, platinum-resistant epithelial…